Speciality Medicines Ltd

Speciality Medicines Ltd has submitted its Annual Report for the financial year 2025-26, as per Regulation 34(1) of SEBI (Listing Obligations and Disclosures requirements) Regulations, 2015. The report includes details on corporate information, board and director's reports, CSR activities, related party transactions, employee particulars, secretarial audit report, management discussion and analysis, standalone financial statements (Balance Sheet, Profit & Loss, Cash Flow), and the Notice of the Annual General Meeting. The company was formerly known as Speciality Medicines Private Limited and its CIN is L85300GJ2021PLC120022. Key managerial personnel include a CFO and Company Secretary.

Speciality Medicines Ltd has announced its 5th Annual General Meeting (AGM) scheduled for September 28, 2026, at 11:00 AM IST. The meeting will be conducted entirely through Video Conferencing (VC) / Other Audio-Visual Means (OAVM). Key agenda items include the adoption of audited financial statements for the fiscal year ended March 31, 2026, and the reappointment of Mr. Sumit Babubhai Goyani as a Director. The company is facilitating remote e-voting from September 25 to September 27, 2026, with voting also available during the AGM for eligible shareholders. The notice is available on the company's website.

Speciality Medicines Ltd announced the outcome of its board meeting held on September 03, 2026. The board approved the draft Directors' Report for the financial year 2025-26 and its annexures for inclusion in the Annual Report. Additionally, the company decided to convene its 5th Annual General Meeting (AGM) on September 28, 2026, to be held via Video Conferencing/Other Audio-Visual Means. NSDL has been appointed as the Remote E-Voting Agency, and CS Hardikkumar Jetani will serve as the Scrutinizer for the AGM's voting process. The Register of Members and Share Transfer Books will remain open.

Speciality Medicines Limited has secured regulatory approval from Ethiopia's health authority for two new speciality pharmaceutical formulations: Olanzapine Tablets 5 mg (Olazyn 5) and Diazepam Tablets 5 mg (Diazem 5). This expands the company's registered product portfolio in Ethiopia to 12 formulations, further strengthening its export footprint in the African region. The approvals are valid for 5 years and add to the company's CNS therapeutic portfolio. This move is part of Speciality Medicines' broader export expansion strategy, with additional filings under review in multiple overseas markets. The company aims to deepen its international presence and support long-term export growth.

Speciality Medicines Ltd announced it has received regulatory approval from Ethiopia's health authority for two new pharmaceutical formulations: Olanzapine Tablets 5 mg (Olazyn 5) and Diazepam Tablets 5 mg (Diazem 5). This approval expands the company's registered product portfolio in Ethiopia to 12 formulations. The company also noted its presence in Peru with 2 registered formulations, highlighting its growing international product portfolio and progress in key export markets. A press release regarding this approval has also been submitted.

Speciality Medicines Ltd has appointed Capital Bridge Advisory Service Private Limited, operating under the brand Capital Bridge Advisors, as its Investor and Public Relations Agency. This strategic move aims to enhance the company's investor relations and capital market communication efforts. The agency will focus on fostering engagement with the investment community, promoting transparency, and ensuring effective communication with stakeholders. This appointment underscores the company's commitment to strengthening its investor relations framework in line with evolving market expectations.

Speciality Medicines Limited (SPML) announced its audited standalone financial results for the half-year and full financial year ended March 31, 2026. For the full year, the company reported Revenue from Operations of ₹7,528.51 Lakh and a Profit for the period of ₹1,303.29 Lakh. For the half-year ended March 31, 2026, Revenue from Operations stood at ₹4,478.34 Lakh, with a Profit for the period of ₹818.27 Lakh. The Board of Directors approved these results, along with the audited standalone financial statements, and noted the utilization of Initial Public Issue (IPO) proceeds in line with the prospectus. The Auditor's Report was issued with an unmodified opinion.

Speciality Medicines Limited (SPML) announced the outcome of its Board Meeting held on May 28, 2026. The Board approved and took on record the Audited Standalone Financial Statements and Results for the half-year and financial year ended March 31, 2026, along with the Auditor's Report, which had an unmodified opinion. For the financial year ended March 31, 2026, the company reported Revenue from Operations of ₹7,528.51 Lakh and a Profit for the period of ₹1,303.29 Lakh. The Board also noted the utilization of Initial Public Issue (IPO) proceeds for the same period, confirming adherence to the objects stated in the prospectus.

Speciality Medicines Ltd has scheduled a Board of Directors meeting on May 28, 2026, to consider and approve the audited standalone financial statements and results for the financial year ended March 31, 2026. The trading window for insiders has been closed from April 1, 2026, and will reopen 48 hours after the board meeting concludes.

Niraj Shah acquired shares of Speciality Medicines Limited, as disclosed under Regulation 29(1) of the SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011. The acquisition involved 87,85,796 equity shares of ₹10 each, amounting to ₹8,78,57,960. After the acquisition, Niraj Rajnikant Shah holds 5,47,000 shares, representing 6.22% of the total share/voting capital of Speciality Medicines Limited.